CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 576 enrolled
Drug / intervention
ABP 938 +1 moredrug
Likely dose
ABP 938 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04270747
NCT04270747Phase 3Completed
CompareCT.gov

A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration

Amgen·interventional·Posted Feb 17, 2020·Updated Sep 10, 2025

In Brief

A Phase 3 clinical trial evaluating ABP 938 and Aflibercept for Neovascular (Wet) Age-related Macular Degeneration (AMD). Completed, enrolled 576 participants across 118 sites in 18 countries.

Detailed Summary

The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular (Wet) Age-related Macular Degeneration (AMD)
CountriesCanada, Czechia, Estonia, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Poland, Serbia, Slovakia, South Korea, Spain, United States
CollaboratorsParexel

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 17, 2020
Enrollment StartJun 22, 2020
Primary CompletionJul 18, 2022
Study CompletionJan 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.4 years ago

Interventions

ABP 938drug

Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

Afliberceptdrug

Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks